Use of bisphosphonates in the management of postmenopausal osteoporosis

Annals of the New York Academy of Sciences

Volumn 1218, Issue 1, 2011, Pages 15-32

  Papapoulos, Socrates E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bisphosphonates; Bone remodeling; Fractures; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; JAW OSTEONECROSIS; MEDICAL INFORMATION; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; RISK FACTOR; TREATMENT PLANNING; TREATMENT RESPONSE; VERTEBRA FRACTURE;

EID: 79551518845     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05767.x     Document Type: Article

References (118)

1. 1993. Consensus development conference on osteoporosis. Am. J. Med. 95: 1S-78S.
2. Felsenberg, D. & S. Boonen 2005. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin. Ther. 27: 1-11.
3. Bouxsein, M.L. 2005. Determinants of skeletal fragility. Best Pract. Res. Clin. Rheumatol. 19: 897-911.
4. Seeman, E. & P.D. Delmas 2006. Bone quality: the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354: 2250-2261.
5. Recker, R., J. Lappe, K.M. Davies, et al 2004. Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J. Bone Miner. Res. 19: 1628-1633.
6. Eriksen, E.F., B. Langdahl, A. Vesterby, et al 1999. Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J. Bone Miner. Res. 14: 1217-1221.
7. Parfitt, A.M. 2002. High bone turnover is intrinsically harmful: two paths to a similar conclusion. The Parfitt view. J. Bone Miner. Res. 17: 1558-1559.
8. Parfitt, A.M. 2001. Skeletal heterogeneity and the purpose of bone remodeling: implications for the understandimg of osteoporosis. In Osteoporosis. 2nd ed. R. Marcus, D. Feldman & J. Kelsey, Eds.: 433-447. Academic Press. San Diego.
9. Brumsen, C., S.E. Papapoulos, P. Lips, et al 2002. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J. Bone Miner. Res. 17: 1057-1064.
10. Mellstrom, D.D., O.H. Sorensen, S. Goemaere, et al 2004. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif. Tissue Int. 75: 462-468.
11. Delmas, P.D., R.R. Recker, C.H. Chesnut III, et al 2004. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos. Int. 15: 792-798.
12. Bone, H.G., D. Hosking, J.P. Devogelaer, et al 2004. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350: 1189-1199.
13. Hochberg, M.C., S. Greenspan, R.D. Wasnich, et al 2002. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metab. 87: 1586-1592.
14. Bauer, D.C., D.M. Black, P. Garnero, et al 2004. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19: 1250-1258.
15. Eastell, R., I. Barton, R.A. Hannon, et al 2003. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18: 1051-1056.
16. Moher, D., K.F. Schulz & D. Altman 2001. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285: 1987-1991.
17. Black, D.M., S.R. Cummings, D.B. Karpf, et al.; Fracture Intervention Trial Research Group. 1996. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535-1541.
18. Cummings, S.R., D.M. Black, D.E. Thompson, et al 1998. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280: 2077-2082.
19. Liberman, U.A., S.R. Weiss, J. Broll, et al.; The Alendronate Phase III Osteoporosis Treatment Study Group. 1995. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333: 1437-1443.
20. Harris, S.T., N.B. Watts, H.K. Genant, et al.; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. 1999. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282: 1344-1352.
21. Reginster, J.Y. 2001. Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women. Clin. Exp. Rheumatol. 19: 121-122.
22. Chesnut III, C.H., A. Skag, C. Christiansen, et al 2004. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19: 1241-1249.
23. McCloskey, E., P. Selby, M. Davies, et al 2004. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J. Bone Miner. Res. 19: 728-736.
24. Felsenberg, D., P. Miller, G. Armbrecht, et al 2005. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Bone 37: 651-654.
25. Black, D.M., D.E. Thompson, D.C. Bauer, et al.; FIT Research Group. 2000. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J. Clin. Endocrinol. Metab. 85: 4118-4124.
26. Roux, C., E. Seeman, R. Eastell, et al 2004. Efficacy of risedronate on clinical vertebral fractures within six months. Curr. Med. Res. Opin. 20: 433-439.
27. Cranney, A., G. Wells, A. Willan, et al 2002. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. 23: 508-516.
28. Cranney, A., P. Tugwell, J. Adachi, et al 2002. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr. Rev. 23: 517-523.
29. Adachi, J.D., R. Rizzoli, S. Boonen, et al 2005. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin. Exp. Res. 17: 150-156.
30. Wells, G.A., A. Cranney, J. Peterson, et al 2008. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 1: CD00115.
31. Wells, G., A. Cranney, J. Peterson, et al 2008. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 1: CD004523.
32. McCloskey, E.V., M. Beneton, D. Charlesworth, et al 2007. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J. Bone Miner. Res. 22: 135-141.
33. McClung, M.R., P. Geusens, P.D. Miller, et al.; Hip Intervention Program Study Group. 2001. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med. 344: 333-340.
34. Pols, H.A., D. Felsenberg, D.A. Hanley, et al.; Fosamax International Trial Study Group. 1999. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int. 9: 461-468.
35. Karpf, D.B., D.R. Shapiro, E. Seeman, et al.; Alendronate Osteoporosis Treatment Study Groups. 1997. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 277: 1159-1164.
36. Papapoulos, S.E., S.A. Quandt, U.A. Liberman, et al 2005. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. 16: 468-474.
37. Boonen, S., R.F. Laan, I.P. Barton, et al 2005. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 16: 1291-1298.
38. Nguyen, N.D., J.A. Eisman & T.V. Nguyen 2006. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J. Bone Miner. Res. 21: 340-349.
39. Harrington, J.T., L.G. Ste-Marie, M.L. Brandi, et al 2004. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue Int. 74: 129-135.
40. Caro, J.J., K.J. Ishak, K.F. Huybrechts, et al 2004. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 15: 1003-1008.
41. Siris, E.S., S.T. Harris, C.J. Rosen, et al 2006. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81: 1013-1022.
42. Schnitzer, T., H.G. Bone, G. Crepaldi, et al.; Alendronate Once-Weekly Study Group. 2000. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging (Milano) 12: 1-12.
43. Brown, J.P., D.L. Kendler, M.R. McClung, et al 2002. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 71: 103-111.
44. Cramer, J.A., M.M. Amonkar, A. Hebborn, et al 2005. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr. Med. Res. Opin. 21: 1453-1460.
45. Recker, R.R., R. Gallagher & P.E. MacCosbe 2005. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin. Proc. 80: 856-861.
46. Bone, H.G., S. Adami, R. Rizzoli, et al 2000. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin. Ther. 22: 15-28.
47. Cremers, S.C., G. Pillai & S.E. Papapoulos 2005. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet. 44: 551-570.
48. Watts, N.B., S.T. Harris, H.K. Genant, et al 1990. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323: 73-79.
49. Harris, S.T., N.B. Watts, R.D. Jackson, et al 1993. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am. J. Med. 95: 557-567.
50. Cranney, A., G. Guyatt, N. Krolicki, et al 2001. A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporos Int. 12: 140-151.
51. Reginster, J.Y., C. Christiansen, C. Roux, et al 2001. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos. Int. 12: 169-177.
52. Recker, R., J.A. Stakkestad, C.H. Chesnut III, et al 2004. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34: 890-899.
53. Papapoulos, S.E. & R.C. Schimmer 2007. Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann. Rheum. Dis. 66: 853-858.
54. Hernandez, C.J., G.S. Beaupre, R. Marcus, et al 2002. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing. J. Bone Miner. Res. 17: 1662-1666.
55. Reginster, J.Y., K.M. Wilson, E. Dumont, et al 2005. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J. Clin. Endocrinol. Metab. 90: 5018-5024.
56. Miller, P.D., M.R. McClung, L. Macovei, et al 2005. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J. Bone Miner. Res. 20: 1315-1322.
57. Reginster, J.Y., S. Adami, P. Lakatos, et al 2006. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann. Rheum. Dis. 65: 654-661.
58. Delmas, P.D., S. Adami, C. Strugala, et al 2006. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 54: 1838-1846.
59. Cranney, A., G.A. Wells, E. Yetisir, et al 2009. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int. 20: 291-297.
60. Harris, S.T., W.A. Blumentals, P.D. Miller 2008. Ibandronate and the risk of non-vertebral fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr. Med. Res. Opin. 24: 237-245.
61. Sebba, A.I., R.D. Emkey, J.D. Kohles & P.N. Sambrook 2009. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44: 423-427.
62. Reid, I.R., J.P. Brown, P. Burckhardt, et al 2002. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346: 653-661.
63. Khan, S.A., J.A. Kanis, S. Vasikaran, et al 1997. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J. Bone Miner. Res. 12: 1700-1707.
64. Black, D.M., P.D. Delmas, R. Eastell, et al 2007. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356: 1809-1822.
65. Lyles, K.W., C.S. Colon-Emeric, J.S. Magaziner, et al 2007. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357: 1799-1809.
66. Black, D.M., A.V. Schwartz, K.E. Ensrud, et al 2006. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296: 2927-2938.
67. Schwartz, A.V., D.C. Bauer, S.R. Cummings, et al 2010. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J. Bone Miner. Res. 25: 976-982.
68. McClung, M.R., R.D. Wasnich, D.J. Hosking, et al 2004. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J. Clin. Endocrinol. Metab. 89: 4879-4885.
69. Wasnich, R.D., Y.Z. Bagger, D.J. Hosking, et al 2004. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11: 622-630.
70. Bagger, Y.Z., L.B. Tanko, P. Alexandersen, et al 2003. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33: 301-307.
71. Landman, J.O., N.A. Hamdy, E.K. Pauwels, et al 1995. Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate. J. Clin. Endocrinol. Metab. 80: 3465-3468.
72. Papapoulos, S.E. & S.C. Cremers 2007. Prolonged bisphosphonate release after treatment in children. N. Engl. J. Med. 356: 1075-1076.
73. Watts, N.B., A. Chines, W.P. Olszynski, et al 2008. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 19: 365-372.
74. Parfitt, A.M. 2004. What is the normal rate of bone remodeling? Bone 35: 1-3.
75. Heaney, R.P. 2003. Is the paradigm shifting? Bone 33: 457-465.
76. Parfitt, A.M. 2003. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr. Opin. Nephrol. Hypertens. 12: 387-403.
77. Whyte, M.P., M.A. Bergfeld, W.A. Murphy, et al 1982. Postmenopausal osteoporosis. A heterogeneous disorder as assessed by histomorphometric analysis of Iliac crest bone from untreated patients. Am. J. Med. 72: 193-202.
78. Foldes, J., M.S. Shih & A.M. Parfitt 1990. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J. Bone Miner. Res. 5: 1063-1067.
79. Podenphant, J. & U. Engel 1987. Regional variations in histomorphometric bone dynamics from the skeleton of an osteoporotic woman. Calcif. Tissue Int. 40: 184-188.
80. Recker, R.R., D.B. Kimmel, A.M. Parfitt, et al 1988. Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females. J. Bone Miner. Res. 3: 133-144.
81. Flora, L., G.S. Hassing, A.M. Parfitt, et al 1980. Comparative skeletal effects of two diphosphonates in dogs. Metab. Bone Dis. Relat. Res. 2(suppl): 389-407.
82. Flora, L., G.S. Hassing, G.G. Cloyd, et al 1981. The long-term skeletal effects of EHDP in dogs. Metab. Bone Dis. Relat. Res. 3: 289-300.
83. Mashiba, T., C.H. Turner, T. Hirano, et al 2001. Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29: 271-278.
84. Ding, M., J.S. Day, D.B. Burr, et al 2003. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif. Tissue Int. 72: 737-744.
85. Mashiba, T., S. Hui, C.H. Turner, et al 2005. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs. Calcif. Tissue Int. 77: 180-185.
86. Komatsubara, S., S. Mori, T. Mashiba, et al 2003. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J. Bone Miner. Res. 18: 512-520.
87. Komatsubara, S., S. Mori, T. Mashiba, et al 2004. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J. Bone Miner. Res. 19: 999-1005.
88. Mashiba, T., C.H. Turner, T. Hirano, et al 2001. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524-531.
89. Mashiba, T., T. Hirano, C.H. Turner, et al 2000. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15: 613-620.
90. Allen, M.R., K. Iwata, R. Phipps, et al 2006. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39: 872-879.
91. Chapurlat, R.D., M. Arlot, B. Burt-Pichat, et al 2007. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: A bone biopsy study. J. Bone Miner. Res. 22, 1502-1509.
92. Stepan, J.J., D.B. Burr, I. Pavo, et al 2007. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41: 378-385.
93. Chapurlat, R.D. & P.D. Delmas 2009. Bone microdamage: a clinical perspective. Osteoporos Int. 20: 1299-1308.
94. Giusti, A., N.A.T. Hamdy & S.E. Papapoulos 2010. Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 47: 169-180.
95. Shane, E. 2010. Evolving data about ubtrochanteric fractures and bisphosphonates. N. Engl. J. Med. 362: 1825-1827
96. Chavassieux, P.M., M.E. Arlot, C. Reda, et al 1997. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100: 1475-1480.
97. Borah, B., T.E. Dufresne, E.L. Ritman, et al 2006. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39: 345-352.
98. Bone, H.G., R.W. Downs, Jr., J.R. Tucci, et al 1997. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J. Clin. Endocrinol. Metab. 82: 265-274.
99. Recker, R.R., R.S. Weinstein, C.H. Chesnut, III, et al 2004. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos. Int. 15: 231-237.
100. Bravenboer, N., S.E. Papapoulos, P. Holzmann, et al 1999. Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos. Int. 9: 489-493.
101. Borah, B., T.E. Dufresne, P.A. Chmielewski, et al 2004. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34: 736-746.
102. Eriksen, E.F., F. Melsen, E. Sod, et al 2002. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31: 620-625.
103. Bone, H.G., S.L. Greenspan, C. McKeever, et al.; Alendronate/Estrogen Study Group. 2000. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J. Clin. Endocrinol. Metab. 85: 720-726.
104. Recker, R.R., P.D. Delmas, J. Halse, et al 2008. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 23: 2-5.
105. Black, D.M., M.P. Kelly, H.K. Genant, et al 2010. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med. 362: 1761-1771.
106. Bilezikian, J., A. Klemes, S. Silverman & F. Cosman 2009. Subtrochanteric fracture reports coincident with risedronate use. J. Bone Miner. Res. 24(suppl 1).
107. Ettinger, B., J. San Martin, G. Crans, et al 2004. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J. Bone Miner. Res. 19: 745-751.
108. Obermaier-Pietsch, C.B., F. Marin, E. McCloskey, et al 2007. Effects of prior antiresorptive therapy on markers of bone formation after 6 months of teriparatide treatment in postmenopausal women with osteoporosis: results from the Eurofors trial. Calcif. Tissue Int. 80(suppl 1): s137.
109. Miller, P.D., P.D. Delmas, R. Lindsay, et al 2008. Early responsiveness of women with osteoporosisd to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93: 3785-3793.
110. McClung, M., R. Recker, P. Miller, et al 2007. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41: 122-128.
111. Bilezikian, J.P. 2006. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N. Engl. J. Med. 355: 2278-2281.
112. Reid, I.R. 2009. Osteonecrosis of the jaw: who gets it and why? Bone 44: 4-10.
113. Felsenberg, D., B. Hoffmeister, T. Jung, et al 2009. Osteonecrosis of the jaw in patients with osteoporosis: a remarkable risk of osteoporosis treatment? 44: S235-S236.
114. Abrahamsen, B. 2010. Adverse effects of bisphosphonates. Calcif. Tissue Int. 86: 421-435.
115. Russell, R.G.G., N.B. Watts, F.H. Ebetino & M.J. Rogers 2008. Mecahanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19: 733-759.
116. Wysowski, D.K. 2009. Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med. 360: 89-90.
117. Cummings, S.R., A.V. Schwartz & D.M. Black 2007. Alendronate and atrial fibrillation. N. Engl. J. Med. 356: 1895-1896.
118. Papapoulos, S. 2008. Bisphosphonates for postmenopausal osteoporosis. In Primer of Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th edition. C.J. Rosen, Ed. ASBMR. Washington D.C. Q1: 237-244.